Bill Ackman Reveals Pershing Square's 6% Stake In Domino's

Shares of Domino's Pizza (DPZ) are trading high on Wednesday after hedge fund Pershing Square Capital's CEO Bill Ackman revealed that the company has bought 6 percent stake in the fast-food chain.

Ackman made this revelation while speaking at the virtual event Future of Everything Festival, which was organized by the Wall Street Journal. Pershing Square bought the shares at around $330 per share.

The investor said that he bought the pizza chain's shares when they "dropped dramatically in price for reasons we didn't understand and we were able to swap Starbucks for Domino's Pizza."

"We didn't get as much as we would like but we own a little under 6%," Ackman added.

The billionaire investor said that the company had sold its stake in coffee chain Starbucks Corp. (SBUX)and then invested in Domino's Pizza. The Starbucks shares were sold after its business was back on track following the pandemic.

Commenting on the sell-off, Ackman said, "We sold Starbucks. It got to a price that it was hard to earn the excess return we like to earn .The stock just recovered too quickly."

The investor said that he remains bullish about the pizza chain's breakthrough in technology and delivery. "Domino's is a pure franchising company and interestingly they were the first to invest in technology and delivery," he added.

The stock is currently trading at $425.26, up $0.92 or 0.69 percent on the NYSE.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Southwest Airlines' flights across the United States were delayed for hours on Monday evening due to technical issue in a weather information system by a third-party weather data provider. The airline later resumed flight operations after solving the issue, but there were delays. The United Kingdom's Competition and Markets Authority or CMA announced Tuesday that it has launched a market study into mobile ecosystems of technology giants Apple Inc. (AAPL) and Google, Inc. (GOOG) over concerns they have market power which is harming users and other businesses. The CMA is taking... Eli Lilly and Co. (LLY) announced Tuesday that it will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant), an orally disintegrating tablet patients take every other day. This study will help to advance the science of migraine treatment...
Follow RTT